Skip to main content
Premium Trial:

Request an Annual Quote

Althea Technologies Spins out Molecular Dx Business

NEW YORK (GenomeWeb News) – Pharmaceutical services company Althea Technologies said yesterday it has spun out its molecular diagnostics and biomarker business into an independent company called Althea Diagnostics. 
The new company, which will be situated at Althea Technologies’ campus in San Diego, will commercialize a quantitative gene measurement technology and will seek to develop other tools and applications aimed at speeding up the development of molecular diagnostic tests.
Althea Diagnostics is developing a test for differential diagnosis of pediatric solid tumors along with other biomarker sets for use in cancer management.
Company Co-founder François Ferre said in a statement that the move to create a diagnostics-focused company was “a situation of technology and timing,” and said the attraction of the molecular diagnostics market was “too strong to resist.”
The spin-out also will continue to offer lab services to pharmaceutical companies and contract research organizations, including its Express Pathway suite, which is used to identify molecules, explore treatment pathways, and build sets of markers that may be of clinical utility.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.